Switching from pergolide to pramipexole in patients with Parkinson's disease

Journal of Neural Transmission

Volumn 108, Issue 1, 2001, Pages 63-70

  Hanna, P A ^a   Ratkos, L ^b   Ondo, W G ^b   Jankovic, J ^b  

^a NEW JERSEY NEUROSCIENCE INSTITUTE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dopamine agonists; Parkinson's disease; Pergolide; Pramipexole; Ropinirole; Therapy

Indexed keywords

CARBIDOPA; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; SLEEP DISORDER;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; BENZOTHIAZOLES; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; EDEMA; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; NAUSEA; PARKINSON DISEASE; PERGOLIDE; PROSPECTIVE STUDIES; RECEPTORS, DOPAMINE; SWEATING; THIAZOLES; TREATMENT OUTCOME;

EID: 0034927015     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170097     Document Type: Article

References (24)

1. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline
2. An overnight switch to ropinirole therapy in patients with Parkinson's disease
3. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease
4. Falling asleep at the wheel: A serious side effect of pramipexole and ropinirole
5. Switching dopamine agonists in advanced Parkinson's disease. Is rapid titration preferable to slow?
6. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group
7. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations
8. New and emerging therapies for Parkinson disease
9. Comparison of pergolide and bromocriptine therapy in parkinsonism
10. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study
11. Antidepressant effects of pramipexole, a novel dopamine receptor agonist
12. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease
13. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease
14. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study
15. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study
16. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease
17. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial
18. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group
19. Clinical characteristics of pramipexole-induced peripheral edema
20. Pharmacological profile of ropinirole: A nonergoline dopamine agonist
21. Intranasal apomorphine in parkinsonian on-off fluctuations
22. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease
23. The mesolimbic dopamine system as a target for rapid antidepressant action